|
Zervixkarzinom Früherkennung: Mit dem von der US-Arzneimittelbehörde
Food and Drug Administration (FDA) zugelassenen LUMA-System kann
ein Gebärmutterhalskrebs
nun noch zuverlässiger als bisher möglich entdeckt werden.
Ein
innovatives technisches Gerät wird in Zukunft
Ärzten dabei helfen,
Gebärmutterhals-Krebs (Zervixkarzinom) frühzeitig zu entdecken.
Das LUMA Cervical Imaging System der
Firma MediSpectra
kann Krebszellen auch dann entdecken, wenn sie mit den heute üblichen
Diagnoseverfahren Pap-Test und Kolposkopie übersehen werden.

Die
US-Arzneimittelbehörde FDA gab in einem Newsletter bekannt, daß
in einer Studie bei 193 Frauen mit auffälligem Abstrich vom Muttermund
(Pap Smear/Pap-Test) 50 Frühfälle von Muttermundkrebs entdeckt
wurden. Von diesen 50 Fällen wurden 9 ausschließlich durch das
LUMA-System entdeckt, die vorher bei der auch in Deutschland üblichen
Scheidenspiegelung (Kolposkopie) übersehen worden waren.
Mit
Hilfe des LUMA-Systems wir der Muttermund mit Licht bestrahlt
das vom Gewebe unterschiedlich reflektiert wird. Dabei ist es
möglich verdächtige Stellen zu entdecken, die bei der Kolposkopie
nicht auffällig waren. An diesen Stellen wird dann vom Arzt eine
Gewebeprobe entnommen, die feingeweblich untersucht wird. Danach
entscheiden der erfahrene Pathologe, ob es sich um Krebszellen
handelt oder nicht.
Imaging
System Helps Detect Cervical Pre-Cancer
FRIDAY,
March 17 - A new system to help doctors identify pre-cancerous
cells on a woman's cervix has been approved by the U.S. Food and
Drug Administration.
MediSpectra's
LUMA Cervical Imaging System can detect pre-cancerous cells missed
by colposcopy, a diagnostic tool used on women with an abnormal
Pap smear. In 50 cases of pre-cancer detected during a clinical
study of 193 women, nine were caught by the LUMA system after
being missed by colposcopy, the FDA said in a news release.
LUMA
shines a light on the cervix and evaluates how different portions
of cervical tissue respond to that light, the agency said. This
and colposcopy results help doctors decide where to biopsy.
"Use
of the LUMA device is not a substitute for a thorough colposcopic
exam," the agency stressed.
If
detected early, cervical cancer is "highly preventable,"
the FDA said. The American Cancer Society estimates that in 2006,
about 9,710 cases of invasive cervical cancer will be diagnosed
in the United States, and about 3,700 U.S. women will die from
the disease.
More information
To learn more about cervical cancer, visit the American Cancer
Society
****
American
Cancer Society
Detailed
Guide: Cervical Cancer
What
Are the Key Statistics About Cervical Cancer?
The
American Cancer Society estimates that in 2006, about 9,710
cases of invasive cervical cancer will be diagnosed in the
United States. Some researchers estimate that noninvasive cervical
cancer (carcinoma in situ) is about 4 times more common
than invasive cervical cancer.
About
3,700 women will die from cervical cancer in the United
States during 2006. Cervical cancer was once one of the most common
causes of cancer death for American women. Between 1955 and 1992,
the number of cervical cancer deaths in the United States dropped
by 74%. The main reason for this change is the increased use
of the Pap test. This screening procedure can find changes in
the cervix before cancer develops. It can also find early cancer
in its most curable stage. The death rate from cervical cancer
continues to decline by nearly 4% a year.
Cervical
cancer tends to occur in midlife. Half of women diagnosed with
this cancer are between the ages of 35 and 55. It rarely occurs
in women younger than 20. Although cervical cancer does affect
young women, many older women do not realize that the risk of
developing cervical cancer is still present as they age. Slightly
over 20% of women with cervical cancer are diagnosed when they
are over 65. It is important for older women to continue having
regular Pap tests at least until age 70, and possibly longer.
See the section, "Can Cervical Cancer Be Prevented?"
for more specific information on current American Cancer Society
screening recommendations.
Cervical
cancer occurs most often in Hispanic women; the rate is over twice
that in non-Hispanic white women. African-American women develop
this cancer about 50% more often than non-Hispanic white women.
The
5-year relative survival rate for the earliest stage of
invasive cervical cancer is 92%. The overall (all stages
combined) 5-year survival rate for cervical cancer is about
73%.
The
5-year survival rate refers to the percentage of patients who
live at least 5 years after their cancer is diagnosed. Five-year
rates are used to produce a standard way of discussing prognosis.
Of course, many people live much longer than 5 years. Five-year
relative survival rates exclude patients dying of other diseases.
This means that anyone who died of another cause, such as heart
disease, is not counted.
Keep
in mind that 5-year survival rates are based on patients diagnosed
and initially treated more than 5 years ago. Improvements in treatment
often result in a more favorable outlook for recently diagnosed
patients.
Revised:
02/09/2006
Website
des Herstellers:
Medispectra
(http://www.medispectra.com/Default.htm)
|